Kahaku Emoto
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate.
Journal: Rheumatology and therapy
Published: November 20, 2023
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate.
Journal: Rheumatology and therapy
Published: March 21, 2023
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
Journal: Rheumatology and therapy
Published: January 04, 2023
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
Journal: Rheumatology and therapy
Published: August 05, 2022
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials.
Journal: Rheumatology and therapy
Published: August 05, 2022
Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan.
Journal: Allergology international : official journal of the Japanese Society of Allergology
Published: September 04, 2018
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Journal: The New England journal of medicine
Published: February 16, 2017
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
Journal: The Journal of rheumatology
Published: November 13, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026